← Eichor
Study identifier: NCT05393791 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC

Condition: Prostatic Neoplasms, Castration-Resistant  ·  Sponsor: Leiden University Medical Center

PhasePhase 2
Planned participants168
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Hormone tablets, abiraterone (Zytiga®) and enzalutamide (Xtandi®) are approved to treat advanced prostate cancer. However, even if these drugs are helpful, their effectiveness usually diminishes over time. Small pilot studies have indicated that using hormone tablets sparingly, for just long enough to control the cancer, followed by a break in treatment and restarting them later, seems to improve how long hormone tablets can control the cancer. This study aims to find out if this pause/restart strategy is better than taking hormone tablets every day continuously. The study will include 168 people with metastatic castrate resistant prostate cancer in the Netherlands and Australia. Patients will be randomly 1:1 assigned between the control group and the experimental group. In the control group, patients will take the treatment with AA/ENZ every day until the prostate cancer doesn't respond anymore to the treatment. In the experimental group, patients will start with daily AA/ENZ until the PSA has declined for \>50%. The treatment will then be paused and monthly PSA measurements will be performed. The treatment will be re-initiated when the PSA has increased to the level of before starting treatment. The treatment will be continued daily until the PSA has again dropped for \>50%. This pause/restart cycle will be repeated until the prostate cancer doesn't respond anymore to the treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Tom van der Hulle, MD PhD  ·  0031715263464  ·  t.van_der_hulle@lumc.nl

Samantha Oakes, Prof.  ·  +61 2 90543600  ·  trials@anzup.org.au

Always discuss trial participation with your own doctor first.

Locations (19)

Border Medical Oncology Research Unit / The Border Cancer HospitalAlbury, New South Wales, AustraliaRecruiting
Chris O'Brien LifehouseCamperdown, New South Wales, AustraliaRecruiting
St George HospitalKogarah, New South Wales, AustraliaRecruiting
Calvary Mater NewcastleNewcastle, New South Wales, AustraliaRecruiting
Genesis Care North ShoreSt Leonards, New South Wales, AustraliaRecruiting
Sydney Adventist HospitalWahroonga, New South Wales, AustraliaRecruiting
Sunshine Coast University HospitalBirtinya, Queensland, AustraliaRecruiting
Mater Hospital BrisbaneSouth Brisbane, Queensland, AustraliaRecruiting
Royal Adelaide HospitalAdelaide, South Australia, AustraliaRecruiting
ICON Cancer CentreAdelaide, South Australia, AustraliaRecruiting
Eastern Health Box HillBox Hill, Victoria, AustraliaRecruiting
Fiona Stanly HospitalMurdoch, Western Australia, AustraliaRecruiting

+ 7 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05393791